Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-6-13
pubmed:abstractText
We evaluated the efficacy and safety of rituximab in an open-label, uncontrolled study of 13 patients with polyneuropathy associated with antibodies to myelin-associated glycoprotein (MAG) and correlated the response to therapy with clinical and laboratory features. One year after rituximab therapy, anti-MAG immunoglobulin M (IgM) titers were significantly reduced. At that time, eight patients (62%) had improved in both the inflammatory neuropathy cause and treatment (INCAT) sensory sumscore and the Medical Research Council sumscore for muscle strength and seven of them also in the INCAT disability score. The improvement in the mean INCAT sensory sumscore was significant at 12 months and correlated with lower anti-MAG antibody at entry and at follow-up. This study suggests that rituximab may be efficacious in patients with anti-MAG associated neuropathy and particularly on sensory impairment and in those with moderately elevated antibody titers. These findings suggest that antibody reduction below a critical level may be necessary to achieve clinical improvement.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1085-9489
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
102-7
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:17565535-Adult, pubmed-meshheading:17565535-Aged, pubmed-meshheading:17565535-Antibodies, Monoclonal, pubmed-meshheading:17565535-Antibodies, Monoclonal, Murine-Derived, pubmed-meshheading:17565535-Antigens, CD19, pubmed-meshheading:17565535-Autoantibodies, pubmed-meshheading:17565535-B-Lymphocyte Subsets, pubmed-meshheading:17565535-B-Lymphocytes, pubmed-meshheading:17565535-Blotting, Western, pubmed-meshheading:17565535-Electromyography, pubmed-meshheading:17565535-Female, pubmed-meshheading:17565535-Flow Cytometry, pubmed-meshheading:17565535-Humans, pubmed-meshheading:17565535-Immunoglobulin M, pubmed-meshheading:17565535-Immunologic Factors, pubmed-meshheading:17565535-Male, pubmed-meshheading:17565535-Middle Aged, pubmed-meshheading:17565535-Muscle Strength, pubmed-meshheading:17565535-Myelin-Associated Glycoprotein, pubmed-meshheading:17565535-Neural Conduction, pubmed-meshheading:17565535-Polyneuropathies
pubmed:year
2007
pubmed:articleTitle
Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.
pubmed:affiliation
Department of Neurosciences, Ophthalmology and Genetics, University of Genova, Genova, Italy. luanabenedetti@libero.it
pubmed:publicationType
Journal Article, Clinical Trial, Multicenter Study